Colonization resistance

Colonization resistance is the mechanism whereby the intestinal microbiota protects itself against incursion by new and often harmful microorganisms.[1][2]

Colonization resistance was first identified in 1967, and it was initially referred to as antibiotic associated susceptibility. It was observed that animals being treated with the antibiotic streptomycin were susceptible to Salmonella enterica at doses 10,000 fold lower than the standard minimal infectious dose.[3] This led to investigations about the mechanisms utilized by endogenous microbial populations that conferred protection against exogenous pathogens attempting to colonize the gut flora.

It has been observed that colonization resistance can occur within the host in a 'direct' or 'indirect' manner.[4] The former refers to particular components of the microbiota directly competing with exogenous pathogens for nutritional niches (e.g. Bacteroides thetaiotaomicron directly competes with Citrobacter rodentium for carbohydrates in the intestinal lumen[5]) or by producing growth inhibitors (e.g. Bacteroides thuringiensis can secrete bacteriocin that directly targets spore-forming Clostridium difficile, thus inhibiting its growth through an unknown mechanism),[6] that directly inhibits the colonizing pathogen. Indirect colonization resistance is thought to be mediated through the induction of immune responses in the host that concomitantly inhibit the colonizing pathogen. An example of this has been observed with B. thetaiotaomicron, which can induce the host to produce antimicrobial C-type lectins REGIIIγ and REGIIIβ, both anti-microbial peptides that target gram-positive bacteria.[7]

References

  1. Wilson, Michael (2005). Microbial inhabitants of humans: their ecology and role in health and disease. Cambridge University Press. ISBN 9780521841580.
  2. Trevor Lawley and Alan Walker, "Intestinal colonization resistance", Immunology, volume 38, pages 1-11, 2013.
  3. Bohnhoff M, Miller CP (1962). "Enhanced Susceptibility to Salmonella Infection in Streptomycin-Treated Mice". Journal of Infectious Diseases. 111 (2): 117–127. doi:10.1093/infdis/111.2.117. PMID 13968487.(subscription required)
  4. Buffie CG, Pamer EG (2013). "Microbiota-mediated colonization resistance against intestinal pathogens". Nature Reviews Immunology. 13 (11): 790–801. doi:10.1038/nri3535. PMC 4194195. PMID 24096337.
  5. Kamada N, Kim YG, Sham HP, Vallance BA, Puente JL, Martens EC, Núñez G (2012). "Regulated virulence controls the ability of a pathogen to compete with the gut microbiota". Science. 336 (6086): 1325–1329. doi:10.1126/science.1222195. PMC 3439148. PMID 22582016.
  6. Rea, MC, Sit CS, Clayton E, O'Connor PM, Whittal RM, Zheng J, Vederas JC, Ross RP, Hill C (2010). "Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile". Proceedings of the National Academy of Sciences of the United States of America. 107 (20): 9352–9357. doi:10.1073/pnas.0913554107. PMC 2889069. PMID 20435915.CS1 maint: uses authors parameter (link)
  7. Cash HL, Whitham CV, Behrendt CL, Hooper LV (25 August 2006). "Symbiotic bacteria direct expression of an intestinal bactericidal lectin". Science. 313 (5790): 1126–1130. doi:10.1126/science.1127119. PMC 2716667. PMID 16931762.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.